New Delhi: Akums Group, India’s largest Contract Development and Manufacturing organization, has announced a strategic long-term agreement with a globally renowned pharmaceutical company to manufacture and supply pharmaceutical formulations in the European market. Under this collaboration, Akums Group will produce and supply multiple SKUs of oral liquid formulations, which the partner company will market across various European countries.
This agreement aligns with Akums’ strategic growth objective to expand its presence in Europe and other regulated markets while supporting the “Make in India” initiative. This agreement helps boost domestic manufacturing capabilities for global markets. The commercial supply of these products is expected to begin in 2027 and will continue to be supplied till 2032. As part of this initiative, Akums Group will initiate the European approval process for its oral liquid manufacturing facility, leveraging this approval to produce the contracted products. The site and product dossier approvals are expected to be received by the end of 2026. Notably, Akums already operates two European-approved facilities for injectables and oral solids.
The total value of this agreement is estimated at €200 million (INR 1,760 crores). As part of the agreement, Akums Group will receive an upfront payment of €100 million (INR 880 crores) for product development and site approval from European authorities.
Speaking on this development, Mr. Sanjeev Jain, Managing Director of Akums said, “It gives us immense pleasure to enter into a strategic collaboration to manufacture and supply a globally renowned brand for one of the largest multinational pharma companies. This opens doors for us to further expand our footprints in regulated markets and replicate the domestic CDMO success globally.”
Mr. Sandeep Jain, Managing Director of Akums added, “These products are currently being manufactured in Europe. Manufacturing these products in India opens further collaboration opportunities with other global pharma companies to optimize their manufacturing costs and make their supply chain robust. This association is the testimony of our manufacturing excellence and our world-class R&D capabilities. With this, we will add one more dosage form to our portfolio, which can be offered in the European market. Akums already have a European-approved facility for tablets, hard gelatin capsules, sachets, ampoules, vials, eye drops, and dry powder injection.”
